TY - JOUR
T1 - An integrated transcriptomic and metabolomic approach to investigate the heterogeneous Candida albicans biofilm phenotype.
AU - Delaney, Christopher
AU - Short, Bryn
AU - Rajendran, Ranjith
AU - Kean, Ryan
AU - Burgess, Karl
AU - Williams, Craig
AU - Munro, Carol A
AU - Ramage, Gordon
N1 - Funding Information:
We are grateful to microbiology colleagues throughout Scotland for submitting isolates. This work was supported by the Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097377/Z/11/Z and by a research fellowship grant from Gilead Sciences. We would also like to acknowledge the funding support of the BBSRC Industrial CASE PhD studentship for Christopher Delaney ( BB/P504567/1 ).
Publisher Copyright:
© 2023 The Authors
PY - 2023/3/15
Y1 - 2023/3/15
N2 -
Candida albicans is the most prevalent and notorious of the
Candida species involved in bloodstream infections, which is characterised by its capacity to form robust biofilms. Biofilm formation is an important clinical entity shown to be highly variable among clinical isolates. There are various environmental and physiological factors, including nutrient availability which influence the phenotype of
Candida species. However, mechanisms underpinning adaptive biofilm heterogeneity have not yet been fully explored. Within this study we have profiled previously characterised and phenotypically distinct
C. albicans bloodstream isolates. We assessed the dynamic susceptibility of these differing populations to antifungal treatments using population analysis profiling in addition to assessing biofilm formation and morphological changes. High throughput methodologies of RNA-Seq and LC-MS were employed to map and integrate the transcriptional and metabolic reprogramming undertaken by heterogenous
C. albicans isolates in response to biofilm and hyphal inducing serum. We found a significant relationship between biofilm heterogeneity and azole resistance (P < 0.05). In addition, we observed that in response to serum our low biofilm forming (LBF)
C. albicans exhibited a significant increase in biofilm formation and hyphal elongation. The transcriptional reprogramming of LBF strains compared to high biofilm forming (HBF) was distinct, indicating a high level of plasticity and variation in stress responses by heterogenous strains. The metabolic responses, although variable between LBF and HBF, shared many of the same responses to serum. Notably, a high upregulation of the arachidonic acid cascade, part of the COX pathway, was observed and this pathway was found to induce biofilm formation in LBF 3-fold. C. albicans is a highly heterogenous bloodstream pathogen with clinical isolates varying in antifungal tolerance and biofilm formation. In addition to this,
C. albicans is capable of highly complex and variable regulation of transcription and metabolic pathways and heterogeneity across isolates further increases the complexity of these pathways. Here we have shown with a dual and integrated approach, the importance of studying a diverse panel of
C. albicans isolates, which has the potential to reveal distinct pathways that can harnessed for drug discovery.
AB -
Candida albicans is the most prevalent and notorious of the
Candida species involved in bloodstream infections, which is characterised by its capacity to form robust biofilms. Biofilm formation is an important clinical entity shown to be highly variable among clinical isolates. There are various environmental and physiological factors, including nutrient availability which influence the phenotype of
Candida species. However, mechanisms underpinning adaptive biofilm heterogeneity have not yet been fully explored. Within this study we have profiled previously characterised and phenotypically distinct
C. albicans bloodstream isolates. We assessed the dynamic susceptibility of these differing populations to antifungal treatments using population analysis profiling in addition to assessing biofilm formation and morphological changes. High throughput methodologies of RNA-Seq and LC-MS were employed to map and integrate the transcriptional and metabolic reprogramming undertaken by heterogenous
C. albicans isolates in response to biofilm and hyphal inducing serum. We found a significant relationship between biofilm heterogeneity and azole resistance (P < 0.05). In addition, we observed that in response to serum our low biofilm forming (LBF)
C. albicans exhibited a significant increase in biofilm formation and hyphal elongation. The transcriptional reprogramming of LBF strains compared to high biofilm forming (HBF) was distinct, indicating a high level of plasticity and variation in stress responses by heterogenous strains. The metabolic responses, although variable between LBF and HBF, shared many of the same responses to serum. Notably, a high upregulation of the arachidonic acid cascade, part of the COX pathway, was observed and this pathway was found to induce biofilm formation in LBF 3-fold. C. albicans is a highly heterogenous bloodstream pathogen with clinical isolates varying in antifungal tolerance and biofilm formation. In addition to this,
C. albicans is capable of highly complex and variable regulation of transcription and metabolic pathways and heterogeneity across isolates further increases the complexity of these pathways. Here we have shown with a dual and integrated approach, the importance of studying a diverse panel of
C. albicans isolates, which has the potential to reveal distinct pathways that can harnessed for drug discovery.
KW - Biofilm
KW - Candida albicans
KW - Metabolomics
KW - Transcriptomics
UR - http://www.scopus.com/inward/record.url?scp=85149850522&partnerID=8YFLogxK
U2 - 10.1016/j.bioflm.2023.100112
DO - 10.1016/j.bioflm.2023.100112
M3 - Article
C2 - 36969800
VL - 5
JO - Biofilm
JF - Biofilm
SN - 2590-2075
M1 - 100112
ER -